3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
7
Completed
7
Terminated
4
Recruiting
4
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
6
Myelodysplastic Syndromes
4
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Melanoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia
1
Carcinoma, Squamous Cell
1
Interventions
Dexamethasone
14
Rituximab
6
Cytarabine
5
venetoclax
4
Lenalidomide
4
Bortezomib
4
Bendamustine Hydrochloride
4
selinexor
3
pomalidomide
3
pembrolizumab
3
ibrutinib
3
fludarabine
3
carfilzomib
3
Paclitaxel
3
Gemcitabine
3
Drug Therapy
3
Cyclophosphamide
3
Calcium Dobesilate
3
ixazomib
2
gilteritinib
2
fludarabine phosphate
2
elotuzumab
2
daratumumab
2
belinostat
2
Tablets
2
Surveys and Questionnaires
2
Panobinostat
2
Oxaliplatin
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Recurrence
×
Decitabine
×
Clear all
NCT05740449
2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2
Withdrawn